New data on RevMed’s Rasonque leave potential opening for other treatments

Data ReadoutnegativeRasonqueNegative

AI Analysis

Summary

Revolution Medicines disclosed new data on Rasonque showing a lower response rate in patients with the most common KRAS mutation in pancreatic cancer compared to the overall patient population, resulting in a 6% stock price decline.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

Patients with the most common KRAS mutation in pancreatic cancer showed lower response rate than overall patient population

Importance:6/10

Sentiment:

-0.70

oncologypancreatic cancerKRAS mutationclinical datastock decline

Related Companies

$RVMD

Read the original article

Published by Endpoints News on October 9, 2026 3:17 PM

Read Original